The Latest Cardiac and Vascular News
Offers cardiac surgeons with a best-in-class biomaterial indicated for pericardial repair and reconstruction, and epicardial support and repair WESTON, Mass., Jan. 5, 2022 /PRNewswire/ — Helios Cardio Inc. announces the Food and Drug Administration (FDA) 510(k) clearance for commercial distribution of CardiaMend™ Pericardial and Epicardial Reconstruction Matrix. CardiaMend™ Pericardial and Epicardial Reconstruction […]
COSIRA-II Trial Designed to Study the Neovasc Reducer™ for Patients with Refractory Angina VANCOUVER and MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced enrollment of the first patient in the COSIRA-II clinical trial. COSIRA-II (COronary SInus Reducer for the Treatment of Refractory Angina) is a pivotal trial […]
Amended study design provides immediate access and clinical benefits for all patients and becomes the first global IDE study for PA pressure-guided heart failure management LISLE, Ill., Jan. 5, 2022 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the […]
3D models will be used to simulate complex valve repairs in preparation for surgical interventions BOSTON, Jan. 5, 2022 /PRNewswire/ — BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals, and the Montreal Heart Institute (MHI), a world-renowned, ultra-specialized cardiology center, announced they are partnering to develop a new cardiovascular training solution to […]
TPG investment to fuel next stage of growth and expansion for Confluent, building on its strong foundation as a leading partner to medical device manufacturers SCOTTSDALE, Ariz. & SAN FRANCISCO–(BUSINESS WIRE)–Confluent Medical Technologies (“Confluent”), a leading materials science, development and manufacturing partner to medical device manufacturers (“OEMs”), today announced that […]
Study evaluates obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, as an adjunct to diet and maximally tolerated lipid-lowering therapy Company is expected to complete enrollment in 2022 and announce data in the first quarter of 2024 NAARDEN, Netherlands–(BUSINESS WIRE)–NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research […]
SHANGHAI, Jan. 1, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized device pioneer in treatment for cardiopulmonary disease, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study, being the first global completed pulmonary hypertension treatment device RCT study. PADN is an innovative radiofrequency ablation technique in treating PH, was […]
SUZHOU, China, Dec. 30, 2021 /PRNewswire/ — On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement (“TSMVR”) technology was successfully carried out in Asia. The implantation of Peijia’s Highlife TSMVR system was performed by Professor Mao Chen and his team of West China Medical Center of Sichuan University as part of a research clinical […]
SUZHOU, China, Dec. 29, 2021 /PRNewswire/ — SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical. With this win-win collaboration, SyMap has full rights to utilize all assets of Pythagoras, including their Renal Nerve Mapping System (ConfidenHT™, CE Mark Approval,) patents, trademarks and expertise. This collaboration will further enhance and consolidate […]
To date, the foundation has funded $15 million of research into congenital heart defects–America’s most common birth defect. NORTHBROOK, Ill., Dec. 28, 2021 /PRNewswire/ — The Children’s Heart Foundation (CHF), the nation’s leading organization dedicated to funding congenital heart defect (CHD) research, will fund over $1,000,000 of research and scientific collaborations in 2021. Every 15 minutes […]
